Memo Therapeutics has raised CHF 5M (€4,2M) to develop its antibody detection technology, which uses whole antibodies to reach difficult targets.
Memo Therapeutics, a spin-off from ETH Zurich, has closed a Series A2 round of CHF 5M (€4,2M). The funding was provided by Redalpine Venture Partners and Zurich Cantonal Bank among other investors and will be used to bring their MemoMAB antibody technology into preclinical and clinical testing with a focus on treating infectious diseases.
The company’s MemoMAB technology generates recombinant copies of the full range of antibodies produced by white blood cells in response to a certain antigen, which can be used to find antibodies with therapeutic potential. By using whole antibodies, Memo’s technology may be more effective than existing approaches for difficult targets, including ion channels and G-protein coupled receptors.
Image by Kateryna Kon/Shutterstock